Antonia S, et al. Overall survival with durvalumab versus placebo after chemoradiotherapy in stage III NSCLC: updated results from PACIFIC. IASLC 2018, abstract PL02.01.
Adjuvant sorafenib na RFA verbetert prognose van HCC-patiënten
aug 2022 | Maag-darm-leveroncologie